Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
STEP (STriatal-Enriched protein tyrosine Phosphatase) is a neuron-specific phosphatase that regulates N-methyl-D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking, as well as ERK1/2, p38, Fyn, and Pyk2 activity. STEP is overactive in several neuropsychiatric and neurodegenerative disorders, including Alzheimer's disease (AD). The increase in STEP activity likely disrupts synaptic function and contributes to the cognitive deficits in AD. AD mice lacking STEP have restored levels of glutamate receptors on synaptosomal membranes and improved cognitive function, results that suggest STEP as a novel therapeutic target for AD. Here we describe the first large-scale effort to identify and characterize small-molecule STEP inhibitors. We identified the benzopentathiepin 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (known as TC-2153) as an inhibitor of STEP with an IC50 of 24.6 nM. TC-2153 represents a novel class of PTP inhibitors based upon a cyclic polysulfide pharmacophore that forms a reversible covalent bond with the catalytic cysteine in STEP. In cell-based secondary assays, TC-2153 increased tyrosine phosphorylation of STEP substrates ERK1/2, Pyk2, and GluN2B, and exhibited no toxicity in cortical cultures. Validation and specificity experiments performed in wild-type (WT) and STEP knockout (KO) cortical cells and in vivo in WT and STEP KO mice suggest specificity of inhibitors towards STEP compared to highly homologous tyrosine phosphatases. Furthermore, TC-2153 improved cognitive function in several cognitive tasks in 6- and 12-mo-old triple transgenic AD (3xTg-AD) mice, with no change in beta amyloid and phospho-tau levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 5×
“of STEP in the initial synaptopathology of AD [6,16,56].”
InfluentialSelf-citationThiol chemistry and specificity in redox signaling
Winterbourn, C. C., & Hampton, M. B. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.004 · Cited by 1,226
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo
Meng, T.-C., Fukada, T., & Tonks, N. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00445-8 · Cited by 1,040
Redox Redux: Revisiting PTPs and the Control of Cell Signaling
Tonks, N. K. (2005) · Cell · doi:10.1016/j.cell.2005.05.016 · Cited by 702
Aβ inhibits the proteasome and enhances amyloid and tau accumulation
Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.014 · Cited by 384
Almeida, C. G., Takahashi, R. H., & Gouras, G. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5078-05.2006 · Cited by 316 · cited 1×
“In addition, STEP is normally ubiquitinated and degraded by the proteasome after NMDAR stimulation [15], and Ab inhibition of the proteasome [42,43] results in a build-up of active STEP [7].”
BackgroundMolecular characterization of a protein-tyrosine-phosphatase enriched in striatum.
Lombroso, P. J., Murdoch, G., & Lerner, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.7242 · Cited by 188
Self-citationStriatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420
Nguyen, T.-H., Liu, J., & Lombroso, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111683200 · Cited by 185 · cited 20×
“These results suggest that TC-2153 does not target homologous PTPs known to dephosphorylate ERK1/2 and Pyk2 when tested in vivo.”
BackgroundResultInfluentialSelf-citationMUÑOZ, J. J., TÁRREGA, C., BLANCO-APARICIO, C., & PULIDO, R. (2003) · Biochemical Journal · doi:10.1042/bj20021941 · Cited by 121 · cited 1×
“mitogen-activated protein kinase (MAPK) family members ERK1/2 and p38 [11,12], the tyrosine kinases Fyn and Pyk2 [13,14], the glutamate receptor GluN2B subunit of NMDARs (formerly termed NR2B) [6,15,16], and the GluA2 subunit of AMPAR (formerly termed GluR2) [16–18].”
BackgroundHendriks, W., Schepens, J., Brugman, C., Zeeuwen, P., & Wieringa, B. (1995) · Biochemical Journal · doi:10.1042/bj3050499 · Cited by 52
Cited by
The Value of Delaying Alzheimer’s Disease Onset
Zissimopoulos, J., Crimmins, E., & St.Clair, P. (2015) · Forum for Health Economics and Policy · doi:10.1515/fhep-2014-0013 · Cited by 267
Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking
Guntupalli, S., Widagdo, J., & Anggono, V. (2016) · Neural Plasticity · doi:10.1155/2016/3204519 · Cited by 110
“A new small molecule inhibitor of STEP 61 , TC-2153, has recently been shown to reverse cognitive deficits in 3xTg AD mice [124].”
BackgroundGiralt, A., Brito, V., Chevy, Q., Simonnet, C., Otsu, Y., Cifuentes-Díaz, C., de Pins, B., Coura, R., Alberch, J., Ginés, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15592 · Cited by 102
“KO mice were cultured for 21–22 days, transfected with plasmids coding GFP or GFP fused to wild-type Pyk2, to Pyk2(1-840), Pyk2(Y402F) or Pyk2-KD (as indicated), and treated with vehicle or glutamate (Glu, 40mM, 3 h).”
MethodPTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease
Giralt, A., de Pins, B., Cifuentes-Díaz, C., López-Molina, L., Farah, A. T., Tible, M., Deramecourt, V., Arold, S. T., Ginés, S., Hugon, J., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.05.020 · Cited by 64
Reelin links Apolipoprotein E4, Tau, and Amyloid‐β in Alzheimer’s disease
Yi, L. X., Zeng, L., Wang, Q., Tan, E. K., & Zhou, Z. D. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102339 · Cited by 41
Metadata
- Authors
- Xu, J., Chatterjee, M., Baguley, T. D., Brouillette, J., Kurup, P., Ghosh, D., Kanyo, J., Zhang, Y., Seyb, K., Ononenyi, C., Foscue, E., Anderson, G. M., Gresack, J., Cuny, G. D., Glicksman, M. A., Greengard, P., Lam, T. T., Tautz, L., Nairn, A. C., Ellman, J. A., & Lombroso, P. J.
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-08-05
- Volume
- 12
- Issue
- 8
- Pages
- e1001923
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- OpenAlex
- W1998328961
- Cited by
- 143
- References
- 10
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer's Disease. https://app.cochat.ai/papers/10.1371/journal.pbio.1001923
- The paper
- Xu, J., Chatterjee, M., Baguley, T. D., Brouillette, J., Kurup, P., Ghosh, D., Kanyo, J., Zhang, Y., Seyb, K., Ononenyi, C., Foscue, E., Anderson, G. M., Gresack, J., Cuny, G. D., Glicksman, M. A., Greengard, P., Lam, T. T., Tautz, L., Nairn, A. C., . . . Lombroso, P. J. (2014). Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer's Disease. PLoS Biology. https://doi.org/10.1371/journal.pbio.1001923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.